Pivanex is an Orally Active HDAC Inhibitor with Antimetastic and Antiangiogenic Properties
Many malignancies, particularly leukemias, are associated with aberrant recruitment of histone deacetylases (HDACs) or with mutations in histone acetyltransferases such as EP300. In addition, Histone acetylation plays a key role…